HEPATOBLASTOMA IN AN 11 YEARS OLD MALE ADOLESCENT

2021 ◽  
pp. 66-67
Author(s):  
S M Sarfaraj ◽  
Ripan Saha ◽  
Md. Maidul Islam ◽  
Malay Kumar Sinha ◽  
Chhanda Datta

Hepatoblastoma is the most common tumour in children under the age of 5 years. Diagnosis is made usually by combination of clinical, laboratory and radiological ndings. Biopsy is the gold standard for diagnosis. We present a case of hepatoblastoma of an 11 years old boy which is unusual in his age

2021 ◽  
Author(s):  
Elizabeth Fisher ◽  
Christian James ◽  
Diana Mosca ◽  
Bart J Currie ◽  
Anna P Ralph

BACKGROUND Acute Rheumatic Fever (ARF) is a critically important condition for which there is no diagnostic test. Diagnosis requires the use of a set of criteria comprising clinical, laboratory, electrocardiographic and echocardiographic findings. The complexity of the algorithm and the fact that clinicians lack familiarity with ARF, make ARF diagnosis ideally suited to an electronic decision support tool. We developed an ARF Diagnosis Calculator to assist clinicians in diagnosing ARF and correctly assigning categories of ‘possible, ‘probable’ or ‘definite’ ARF. OBJECTIVE To evaluate the acceptability and accuracy of the ARF Diagnosis Calculator as perceived by clinicians in Northern Australia where ARF rates are high, and test performance against a ‘gold standard’. METHODS Three strategies were used to provide triangulation of data. Users of the calculator employed at Top End Health Service, Northern Territory, Australia were invited to participate in an online survey about the calculator, and clinicians with ARF expertise were invited to participate in semi-structured interviews. Qualitative data were analysed using inductive analysis. Performance of the calculator in correctly assigning a diagnosis of possible, probable or definite ARF, or not ARF, was assessed using clinical data from 35 patients presenting with suspected ARF. Diagnoses obtained from the calculator were compared using the Kappa statistic with those obtained from a panel of expert clinicians, considered the ‘gold standard’. Findings were shared with developers of the calculator and changes were incorporated. RESULTS Survey responses were available from 23 Top End Health Service medical practitioners, and interview data were available from five expert clinicians. Using a 6-point Likert scale, participants highly recommended the ARF Diagnosis Calculator (median score 6, IQR 1) and found it easy to use (median 5, IQR 1). Participants believed the calculator helped them diagnose ARF (median 5, IQR 1). Valued features included educational content and laboratory test reference ranges. Criticisms included: too many pop-up messages to be clicked through; that it is less helpful in remote areas which lack access to investigation results; and the need for more clarity about actively excluding alternative diagnoses to avoid false-positive ARF diagnoses. Importantly, clinicians with ARF expertise noted that electronic decision making is not a substitute for clinical experience. There was high agreement between the ARF Diagnosis Calculator and the ‘gold standard’ ARF diagnostic process (κ=0.767, 95% CI: 0.568-0.967). However, incorrect assignment of diagnosis occurred in 4/35 (11%) patients highlighting the greater accuracy of expert clinical input for ambiguous presentations. Sixteen changes were incorporated into a revised version of the calculator. CONCLUSIONS The ARF Diagnosis Calculator is an easy-to-use, accessible tool, but it does not replace clinical expertise. Effective resources to support clinicians in diagnosing and managing ARF are critically important for improving the quality of care of ARF.


2018 ◽  
Vol 89 (6) ◽  
pp. A7.2-A7
Author(s):  
Dev Nathani ◽  
Michael H Barnett ◽  
Judith Spies ◽  
John Pollard ◽  
Matthew C Kiernan

IntroductionNerve biopsy remains the gold standard to diagnose vasculitic neuropathy. Conversely, biopsy has imperfect sensitivity and entails risks associated with an invasive procedure. Methods to improve diagnostic accuracy remain important considerations given the severity of the disease, added with the risks associated with subsequent therapy, particularly in ill-defined cases.MethodsClinical, laboratory and neurophysiological parameters were analysed for all patients who subsequently underwent biopsy. Nerve and muscle biopsy reports were assigned pathologic categories of definite, probable, possible or absent vasculitis using standard guidelines. Correlations were assessed between pre-biopsy parameters and subsequent diagnosis of definite or probable vasculitic neuropathy (pathologically confirmed vasculitis).ResultsFrom a cohort of 207 patients who underwent nerve biopsy over 21 months, 70 were suspected of having vasculitic neuropathy prior to biopsy. Of the 70 patients, vasculitis was confirmed as definite (11.4%), probable (15.7%) or possible (10.0%) on neuropathological assessment. The most sensitive parameters for pathologically confirmed vasculitis were the presence of sensorimotor neuropathy (78%) and axonal neuropathy (67%) on nerve conduction studies (NCS) in the overall cohort. Pathologically absent vasculitis was most prevalent in patients with normal NCS (90%), chronic, symmetric symptoms (86%) and demyelinating findings on NCS (79%). The parameters with the strongest associations with pathologically confirmed vasculitis were positive autoantibody serology (50.0% vs 21.1%, p<0.01), anti-neutrophil cytoplasmic antibody (27.3% vs 6.4%, p<0.01), anti-myeloperoxidase antibody (22.7% vs 1.8%, p<0.005) and rheumatoid factor (22.7% vs 2.8%, p<0.005). In patients suspected to have vasculitis, 83.3% of anti-myeloperoxidase antibody positive patients had pathologically confirmed vasculitis. In patients not suspected to have vasculitis, acute symptoms had the strongest association with pathologically confirmed vasculitis (36.4% vs 10.5%, p<0.05).ConclusionSpecific characteristics of symptoms at the time of presentation, combined with the presence of autoantibodies and neurophysiological abnormalities, were predictive of a tissue diagnosis of vasculitic neuropathy.


2004 ◽  
Vol 50 (7) ◽  
pp. 1118-1125 ◽  
Author(s):  
Nancy A Obuchowski ◽  
Michael L Lieber ◽  
Frank H Wians

Abstract Background: ROC curves have become the standard for describing and comparing the accuracy of diagnostic tests. Not surprisingly, ROC curves are used often by clinical chemists. Our aims were to observe how the accuracy of clinical laboratory diagnostic tests is assessed, compared, and reported in the literature; to identify common problems with the use of ROC curves; and to offer some possible solutions. Methods: We reviewed every original work using ROC curves and published in Clinical Chemistry in 2001 or 2002. For each article we recorded phase of the research, prospective or retrospective design, sample size, presence/absence of confidence intervals (CIs), nature of the statistical analysis, and major analysis problems. Results: Of 58 articles, 31% were phase I (exploratory), 50% were phase II (challenge), and 19% were phase III (advanced) studies. The studies increased in sample size from phase I to III and showed a progression in the use of prospective designs. Most phase I studies were powered to assess diagnostic tests with ROC areas ≥0.70. Thirty-eight percent of studies failed to include CIs for diagnostic test accuracy or the CIs were constructed inappropriately. Thirty-three percent of studies provided insufficient analysis for comparing diagnostic tests. Other problems included dichotomization of the gold standard scale and inappropriate analysis of the equivalence of two diagnostic tests. Conclusion: We identify available software and make some suggestions for sample size determination, testing for equivalence in diagnostic accuracy, and alternatives to a dichotomous classification of a continuous-scale gold standard. More methodologic research is needed in areas specific to clinical chemistry.


2020 ◽  
Vol 58 (2) ◽  
pp. 178-187 ◽  
Author(s):  
Mario Plebani ◽  
Giuseppe Banfi ◽  
Sergio Bernardini ◽  
Francesco Bondanini ◽  
Laura Conti ◽  
...  

AbstractSerum or plasma? An old question looking for new answers. There is a continual debate on what type of sample a clinical laboratory should use. While serum is still considered the gold standard and remains the required sample for some assays, laboratories must consider turn-around time, which is an important metric for laboratory performance and, more importantly, plays a critical role in patient care. In addition, a body of evidence emphasise the choice of plasma in order to prevent modifications of some analytes due to the coagulation process and related interferences. Advantages and disadvantages of serum and plasma are discussed on the basis of current literature and evidence. In addition, data are provided on the current utilisation of the samples (serum or plasma) in Italy and in other countries. Finally, a rationale for a possible switch from serum to plasma is provided.


Diagnostics ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 208 ◽  
Author(s):  
Domenico Sambataro ◽  
Gianluca Sambataro ◽  
Francesca Pignataro ◽  
Giovanni Zanframundo ◽  
Veronica Codullo ◽  
...  

The diagnostic assessment of patients with Interstitial Lung Disease (ILD) can be challenging due to the large number of possible causes. Moreover, the diagnostic approach can be limited by the severity of the disease, which may not allow invasive exams. To overcome this issue, the referral centers for ILD organized Multidisciplinary Teams (MDTs), including physicians and experts in complementary discipline, to discuss the management of doubtful cases of ILD. MDT is currently considered the gold standard for ILD diagnosis, but it is not often simple to organize and, furthermore, rheumatologists are still not always included. In fact, even if rheumatologic conditions represent a common cause of ILD, they are sometimes difficult to recognize, considering the variegated clinical features and their association with all possible radiographic patterns of ILD. The first objective of this review is to describe the clinical, laboratory, and instrumental tests that can drive a diagnosis toward a possible rheumatic disease. The secondary objective is to propose a set of first-line tests to perform in all patients in order to recognize any possible rheumatic conditions underlying ILD.


2015 ◽  
Vol 5 (9) ◽  
pp. 756-765
Author(s):  
Shiva Raj K.C.

Inflammatory bowel disease is a group of inflammatory disorders of unknown etiology. Various genetic factors, mucosal immune response, inappropriate activation of immune system driven by the presence of various luminal flora and epithelial defects have been postulated. Crohn disease and Ulcerative colitis are the two most common inflammatory bowel diseases. Since, specific clinical laboratory features are lacking which may help in establishing a diagnosis histopathological diagnosis remains the gold standard. This review highlights the known hypothesis regarding the etiopathogenesis of these two diseases and also describes pertinent histological features.Journal of Pathology of Nepal (2015) Vol. 5, 756-765


2020 ◽  
Vol 2 (1) ◽  
Author(s):  
Mahmood Ul Hassan ◽  
Abdul Rehman Haris ◽  
Amir Hussain ◽  
Mustansar Ali ◽  
Muhammad Hashim Raza

Objective: Laboratory study to assess the correlation of existing Salmonella blood culture isolates with Widal agglutinin titers and EIA-based Typhidot immunoassay antibodies as the gold standard. Materials and Methods: This study was conducted at the department of community medicine KEMU Lahore for six months from June 2017 to November 2018. 2704 blood samples were taken for cultural studies and Widal test in a clinical laboratory among people with symptoms of clinical intestinal fever. Of these, 1497 were isolated from Salmonella; The sera of these patients who did not accompany Typhidot requests were also subjected to spot immunoassay with the informed consent required for bleeding. All sera were stored at 40 ° C until selection. Results: Blood of 802 men (53.6%) and 695 women (46.4%) gave 61.85% S. typhi (n = 926), 31.26% S. Para typhi-A (n = 468) and 6, 88% S. Para typhi. n = 103) insulation. Broad agglutinins were detected in 473 (31.5%) of these people. Without detectable "O" antibodies, 1:80 "H" titers (n = 264: 17.6%) were most commonly observed in children's sera (n = 112; 7.4%). Widal H with agglutinin "O" was recorded in 209 (13.9%) corresponding positive blood cultures, and 104 (6.9%) gave a titre of 1: 320 or more. A total of 1,024 sera (58.4%) did not have detectable Widal antibody. Typhidot immunoglobulin spots (57.1%), negative in 856 sera, were detected in 641 samples (42.8%). IgG-free IgM stains without detectable IgM, IgG stains without IgG were also observed in 22 sera (1.47%) and samples producing S. Para typhi-A isolate (n = 8) and S. Para typhi-B. Conclusion: S. Para typhi-A has often grown in the last decade, suggesting incomplete protective coverage, probably with a monovalent vaccine. Antibodies against Widal and Typhidot agglutinins were detected in the serum of patients with Salmonella growing in blood in 31.5% and 42.8%, respectively. Widal may be misinterpreted because of possible "lower" agglutinins that have not been inoculated, and the EIA immunoassay is particularly limited only to S. typhi. An ICT based Salmonella serotype three indicator is desirable.


Author(s):  
Stefan Siebert ◽  
Sengupta Raj ◽  
Alexander Tsoukas

The spondyloarthropathies (SpA) are heterogeneous multisystem disorders with no single ‘gold standard’ clinical, laboratory, pathological or radiological feature to confirm the diagnosis. A number of criteria have therefore been developed to support clinical practice and research. In this chapter, we highlight the important differences between classification and diagnostic criteria, which are often confused although they have very different applications. We then review some of the major SpA classification criteria including the modified New York criteria for ankylosing spondylitis (AS), the Amor and ESSG criteria for SpA, and the ASAS criteria for axial spondyloarthritis (axSpA). The evolution of these classification criteria has facilitated many significant advances in the field of axSpA and SpA in general. Specifically, the development of classification criteria for axSpA that do not rely on established radiographic damage has allowed biologic therapies to be investigated, and used, in earlier disease and for a wider population of patients.


2018 ◽  
Vol 57 (2) ◽  
pp. 204-209 ◽  
Author(s):  
Maria Salinas ◽  
Maite López-Garrigós ◽  
Emilio Flores ◽  
Javier Lugo ◽  
Carlos Leiva-Salinas

Abstract Background The clinical laboratory plays a crucial role in the diagnosis and monitoring of chronic kidney disease. The quantitative measurement of urine albumin in a spot sample, expressed as ratio per creatinine (ACR) is the most frequently used biomarker for such a purpose. Our aim was to evaluate the diagnostic performances of a strip for measuring ACR for differentiating patients who are candidates for subsequent albumin quantification, and to evaluate the economic effects of its implementation. Methods We systematically measured strip analysis when quantitative urinary albumin was requested. Semiquantitative urinary albumin was measured using a UC-3500 (Sysmex, Kobe, Japan), based on the protein error of a pH indicator. We collected and reviewed all the values of quantified urinary albumin and their corresponding results in ACR strip tests. We calculated the diagnostic indicators for ACR at different albumin and creatinine values using the quantitative ACR measurement as a “gold standard”. We also studied the economic effects based on both tests prices (€1.31 for quantitative albumin plus creatinine, and €0.04 for an albumin strip). Results The study included 9148 patients (mean age 63, 46.3% men). The results at different albumin and creatinine cutoffs showed the best performance when 10 mg/L and above 50 mg/dL, respectively. Based on our results, we would have saved 3506 urine albumin and creatinine tests in the study period, corresponding to €4226.94. Conclusions The present study supports the use of the ACR strip test to identify pathological albuminuria values to be measured through quantitative methods. Considerable economic savings are possible.


Sign in / Sign up

Export Citation Format

Share Document